1

NANETS Regional NET Education: The Multidisciplinary Management of NET Disease

November 12, 2022

7:30am – 4:00pm 

Earn up to 6.75 AMA PRA Category 1 Credits,™ Continuing Nursing Education (ANCC), and MOC accreditation

REGISTER HERE

Location

Hotel Tampa Riverwalk
200 North Ashley Drive
Tampa, FL 33602

Providers

Jointly Provided by Moffitt Cancer Center and the North American Neuroendocrine Tumor Society

Course Directors

Jonathan R. Strosberg, MD, and Taymeyah Al-Toubah, MPH, Moffitt Cancer Center

Special Promotion

Register by Monday, November 7, 2022, to be entered to win free registration and travel to the 2023 NANETS Symposium held Thursday-Saturday, October 5-7, 2023 at the Fairmont Queen Elizabeth, Montreal - Quebec. One winner will be selected at random during the Conference, you must attend the live event to win.

The package includes complimentary registration, up to $750 for round-trip flights, up to $100 for ground transportation, and 3 nights of hotel accommodations. The prize is non-transferable and can not be redeemed for anything other than the listed offerings. 

Overview

Neuroendocrine tumors (NET) are considered to be a rare disease although the frequency of diagnosis has increased over the last ten years. As this is a rare disease, clinicians often do not know how to implement the appropriate care plan and until the last ten years, there was great variability in terms of treatment. The diagnosis, treatment, and management of NETs are time-consuming, complex, and require a multidisciplinary approach. Many healthcare providers who face these challenges are not adequately equipped in their knowledge or experience optimally manage NET disease.

The field of NET research has been evolving with new drug approvals and treatment modalities. In addition, experts in the field of NET disease have continued to develop strategies to improve diagnosis, treatment and management of NET cancers. It is through convening professionals in the areas of oncology, gastroenterology, pulmonology, surgery, radiology and allied fields that the awareness and understanding of NET diseases will expand, resulting in better treatment for NET patients.

Target Audience

This activity is designed for oncologists, gastroenterologists, pulmonologists, surgeons, radiologists, pathologists, primary care physicians, advanced practice nurses, nurses, physician assistants, pharmacists, fellows, students, and other allied health professionals involved with or interested in the treatment of patients with neuroendocrine tumors.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Review current concepts of neuroendocrine tumor pathology, molecular profile, classification, and grading
  • Discuss the various diagnostic processes and use of current and emerging diagnostic tools to determine neuroendocrine tumor type
  • Summarize the current safety and efficacy data of the various surgical, medical and loco-regional approaches in the management of neuroendocrine tumors
  • Recognize the clinical features associated with carcinoid syndrome
  • Apply a multidisciplinary approach to the management of patients with neuroendocrine tumors
  • Review clinical trial data and ongoing studies evaluating novel management strategies for the treatment of neuroendocrine tumors

Program

7:30am - 8:00am
8:00am - 8:10am
Registration and Breakfast
Welcome and Opening Remarks
    • Taymeyah Al-Toubah, MPH, Senior Clinical Research Coordinator, Moffitt Cancer Center
8:10am - 9:00am
Overview of Gastroenteropancreatic and Lung NETs: Background, Epidemiology, Pathology, Imaging, and Endoscopic Diagnosis
    • GI NETs
      Jennifer Chan, MD, MPH, Clinical Director, Gastrointestinal Cancer Center; Director, Program in Carcinoid and Neuroendocrine Tumors; Dana-Farber Cancer Institute
    • Lung NETs
      Robert Ramirez, DO, FACP, Associate Professor of Medicine, Vanderbilt University Medical Center
9:00am - 10:30am
Surgical Treatment of NETs
    • Small Bowel/Mesenteric/Peritoneal Disease
      J. Philip Boudreaux, MD, FACS, Professor of Surgery, Section of Surgical Oncology, Louisiana State University Health Sciences Center
    • Hepatic Cytoreductive Surgery
      Daniel Anaya Saenz, MD, Chief, GI Surgery; Head of Hepatobiliary Section in the Department of Gastrointestinal Oncology; Moffitt Cancer Center
    • Pancreatic NETs
      Mark Bloomston, MD, FACS, Surgical Oncologist, GenesisCare
10:30am - 10:45am
Break
10:45am - 11:40am
Medical Management of NETs
    • Somatostatin Analogs; Targeted Drugs; Ongoing Clinical Trials
      Heloisa Soares, MD, PhD, Co-Physician Leader for GI Oncology, Clinical Trials Office, Huntsman Cancer Institute at the University of Utah
    • Peptide Receptor Radionuclide Therapy (PRRT); Role of Cytotoxic Chemotherapy; Novel Emerging Treatments
      Mauro Cives, MD, Assistant Professor of Medical Oncology, University of Bari, Italy; Research Associate, Moffitt Cancer Center
11:40am - 12:05pm
Liver-Directed Therapy: Ablation and Embolization
    • Ablation Modalities and Indications; TAE vs. TACE vs. TARE: Pros and Cons
      Ghassan El-Haddad, MD, Section Head, Radionuclide Therapy Program, Moffitt Cancer Center
12:05pm - 12:30pm
Poorly-Differentiated NEC
    • First line Metastatic Treatment; Role of Immunotherapy; Multimodality Treatment of Locoregional Disease
      Mintallah Haider, MD, Assistant Member in the Department of Gastrointestinal Oncology and Department of Satellite and Community Oncology, Moffitt Cancer Center
12:30pm - 1:30pm
Lunch
    • Oberndorfer Cup
      Moderated by Thor Halfdanarson, MD, Assistant Program Director, Hematology/Oncology Fellowship Program, Mayo Clinic, and Jonathan Strosberg, MD, Medical Oncologist, Department of Gastrointestinal Oncology; Section Head, Neuroendocrine Division; Chair, Gastrointestinal Department Research Program, Moffitt Cancer Center
1:30pm - 2:00pm
Hormonal Management of NETs
    • Hormonal Syndromes and Symptom Control
      Jaydira Del Rivero, MD, Assistant Research Physician, Developmental Therapeutics Branch, National Cancer Institute
2:00pm - 3:00pm
Additional Important Topics in NETs
    • Carcinoid Heart Disease
      Dany Sayad, MD, Associate Professor, College of Medicine Internal Medicine, University of South Florida
    • Gastric NETs
      Jonathan Strosberg, MD, Medical Oncologist, Department of Gastrointestinal Oncology; Section Head, Neuroendocrine Division; Chair, Gastrointestinal Department Research Program, Moffitt Cancer Center
3:00pm - 4:00pm
Tumor Board
    • Two Case Presentations: Jonathan Strosberg, MD, Moderator
      Panelists
    • Jennifer Chan, MD, MPH, Clinical Director, Gastrointestinal Cancer Center; Director, Program in Carcinoid and Neuroendocrine Tumors; Dana-Farber Cancer Institute
    • Simron Singh, MD, MPH, FRCPC, Medical Oncologist, Affiliate Scientist, Odette Cancer Centre, Sunnybrook Health Sciences Centre
    • Thor Halfdanarson, MD, Assistant Program Director, Hematology/Oncology Fellowship Program, Mayo Clinic
    • Robert Ramirez, DO, FACP, Associate Professor of Medicine, Vanderbilt University Medical Center
    • Erik S. Mittra, MD, PhD, Nuclear Medicine Physician, Professor of Diagnostic Radiology, School of Medicine, Oregon Health & Science University
    • J. Philip Boudreaux, MD, FACS, Professor of Surgery, Section of Surgical Oncology, Louisiana State University Health Sciences Center
4:00pm - 4:05pm
Closing Remarks and Announcement of Prize Winner

Accreditation

This continuing education activity is provided through collaboration between the North American Endocrine Tumor Society (NANETS) and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurse practitioners, and nurses. A statement of participation is available for other attendees.

Physicians, Physician Assistants, and Nurse Practitioners

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the NANETS. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians for ABIM Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation enables the participant to earn up to 6.75 Medical Knowledge only MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.

It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Use of Learner/Participant Data

Participation information will be shared with the applicable certifying board via ACCME PARS.

In order for MOC credit to be reported, evaluations must be completed prior to the close of evaluations.

Nurses

Continuing Nursing Education is provided for this program through the joint providership of AffinityCE and NANETS. AffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC). This activity provides a maximum of 6.75 hours of continuing nursing education credit.

REGISTER HERE

Registration fee:

NANETS Member

$65 - MD, PharmD, Doctoral Level 
$35 - Allied Health
Complimentary - Student/Fellow/Resident

Non-Member

$95 - MD, PharmD, Doctoral Level 
$50 - Allied Health
Complimentary - Student/Fellow/Resident

Cancellation Policy:

A full refund will be made if registration is canceled, in writing, on or before November 1, 2022. On or after November 2, 2022, no refund will be made.

Moffitt Cancer Center and the North American Neuroendocrine Tumor Society reserve the right to modify the activity content, faculty, and activities and reserve the right to cancel this activity if necessary. If the program is canceled, liability is limited to the registration fee.

Questions?

Please contact us with any questions.